Brazikumab
From WikiMD's WELLNESSPEDIA
| Brazikumab | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 1610353-18-8 |
| PubChem | |
| DrugBank | |
| ChemSpider | none |
| KEGG | D10912 |
Brazikumab (MEDI2070) (INN) is a human monoclonal antibody designed for the treatment of Crohn's disease.[1][2]
This drug was developed by MedImmune.
References[edit]
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Brazikumab, American Medical Association.
- ↑ World Health Organization."International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115".WHO Drug Information.2016;30(2)Full text.
